Jabil Posts Financial Results for Q2 FY 2022

Jabil Inc. (NYSE: JBL), reported preliminary, unaudited financial results for its second quarter of fiscal year 2022.

“The Jabil team delivered another strong quarter in Q2, highlighted by outstanding operational execution and skillful management of current supply chain dynamics,” said Chairman and CEO Mark Mondello. “These actions, coupled with strong demand in key end-markets, allowed us to deliver robust financial results year-on-year,” he added.

Second Quarter of Fiscal Year 2022 Highlights:

  • Net revenue: $7.6 billion
  • Diversified Manufacturing Services (DMS) year-on-year revenue growth: 4 percent
  • Electronics Manufacturing Services (EMS) year-on-year revenue growth: 19 percent
  • U.S. GAAP operating income: $313 million
  • U.S. GAAP diluted earnings per share: $1.51
  • Core operating income (Non-GAAP): $344 million
  • Core diluted earnings per share (Non-GAAP): $1.68

Third Quarter of Fiscal Year 2022 Outlook:

• Net revenue

$7.9 billion to $8.5 billion

• U.S. GAAP operating income

$276 million to $336 million

• U.S. GAAP diluted earnings per share

$1.24 to $1.64 per diluted share

• Core operating income (Non-GAAP) (1)

$300 million to $360 million

• Core diluted earnings per share (Non-GAAP) (1)

$1.40 to $1.80 per diluted share

Fiscal Year 2022 Updated Outlook:

“I like what we’re doing and where we’re going. Our strong financial outlook is supported by both strong secular tailwinds and momentum in many of the end-markets we serve,” continued Mondello. “As a result, we are raising our financial outlook for the fiscal year. We now expect FY22 to deliver revenue in the range of $32.6 billion and core EPS of approximately $7.25,” added Mondello.

____________________

(1) Core operating income and core diluted earnings per share exclude anticipated adjustments of $9 million for amortization of intangibles (or $0.06 per diluted share) and $15 million for stock-based compensation expense and related charges (or $0.10 per diluted share).

Indium EMSNow Durafuse x

About The Author